Phase 3 accrues from the six...

Phase 3

accrues from the six-month double-blind, randomized, placebo-controlled Phase 3 clinical trial of Aldurazyme (laronidase), an investigational enzyme replacement therapy for enslaves with mucopolysaccharidosis 1, and preliminary six-month findings from the ongoing open-label extension thought by BioMarin Pharmaceutical Inc. (Novato, CA) and Genzyme General (Cambridge, MA) demonstrated improved pulmonary capacity and positive directions in endurance. All 45 bring under rules who received the performance maintained improvement in pulmonary function, as measured from forced vital capacity, and